Revenue segments as reported by the company.

Sensor and other revenue

Hardware revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Collaborative research and development fee

Selling, general and administrative

Amortization of intangible assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

DexCom

DexCom, Inc. is a medical device manufacturing company, which engages in the design, development and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6 CGM System, DexCom G6 CGM System for Medicare, Software and Mobile apps. The company was founded by John F. Burd on May 1, 1999 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

DexCom excels in Q4 2022, eyes international expansion and margin growth

DexCom's Q4 2022 showcased robust financials, operational efficiency, and strategic advancements. The company is well-positioned for continued growth in 2023, with a focus on international expansion, marketing investments, and margin optimization.

DexCom excels in Q1, eyes international growth and market expansion

DexCom's strong Q1 performance and strategic initiatives position the company for sustained growth.
Balancing cost management, market expansion, and product enhancements will be crucial for future success.
Opportunities in new markets, user segments, and product improvements offer avenues for continued growth.
Overall, DexCom's focus on innovation and customer-centric strategies bode well for its long-term prospects.

DexCom reports robust Q2 earnings, eyes international expansion and new products

DexCom's Q2 performance reflects strong revenue growth and market momentum, supported by successful product launches and international expansion.
The company's focus on innovation, customer satisfaction, and cost reduction initiatives positions it well for continued success and market leadership.
While facing challenges in customer experience and product adoption, DexCom's strategic strengths and growth opportunities signal a promising outlook for the future.

DexCom achieves record Q3 performance and expands market leadership

DexCom's Q3 performance reflects strong revenue growth, operational efficiency, and strategic market expansion efforts, setting new records in financial metrics.
The company's strengths lie in market leadership, product innovation, and proactive market expansion strategies, supported by a strong brand and organizational culture.
While facing challenges in pricing strategies, timeline for revenue contributions, and distribution accessibility, DexCom is well-positioned to capitalize on opportunities in new markets and product launches.
Overall, DexCom's performance, strengths, and proactive approach to challenges and opportunities position it for sustained growth and market leadership in the medical devices sector.

DexCom excels in Q4 2023, eyes growth through strategic initiatives

DexCom's strong financial performance, product launches, and market expansions in 2023 set a solid foundation for future growth.
Strategic investments, competitive advantages, and a focus on margin progression position DexCom for continued success.
Challenges in reimbursement pathways and market penetration are being addressed, while opportunities in expanding coverage and product enhancements are being pursued.

DexCom excels in Q1 2024, eyes global expansion and innovation

DexCom's strong financial performance, strategic market expansions, and product innovations position the company for continued growth and success.
While facing challenges in market penetration and product adoption timelines, DexCom's focus on user experience and healthcare outcomes remains a key strength.
Opportunities lie in international market expansion, product differentiation, and leveraging sensor technology for improved patient care and business growth.

DexCom reports 15% revenue growth but lowers full-year guidance

DexCom faced challenges in customer additions and revenue per customer in the U.S. and below-expectation international performance. Despite this, they reported 15% revenue growth and lowered full-year revenue guidance to 11%-13% organic growth.

DexCom meets revenue targets, Stelo launch successful, challenges ahead

DexCom's Q3 performance met expectations with growth in key areas.
Strong market reception for Stelo presents revenue and growth opportunities.
Challenges exist in managing differing customer expectations and sensor performance.
Opportunities lie in expanding international markets and enhancing customer experiences.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G6, Dexcom G7, Dexcom Stelo, Dexcom Share, Dexcom Real-Time API, and Dexcom ONE. The company was founded by John F. Burd on May 13, 1999 and is headquartered in San Diego, CA.

NEW YORK--(BUSINESS WIRE)---- $DXCM #Investigation--The law firm of Kirby McInerney LLP is investigating potential claims against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM). The investigation concerns whether DexCom, and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [Click here to learn more about the investigation] On July 25, 2024, after the market closed, DexCom announced its second quarter 2024 financial results in a press rele.

Kirby McInerney LLP Announces Investigation of Shareholder Claims Against DexCom, Inc. (DXCM)

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your DexCom investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of DexCom, Inc. (DXCM) on Behalf of Investors

LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of DexCom, Inc. ("DexCom" or "the Company") (NASDAQ:DXCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

DXCM Investors Can Participate In DexCom, Inc. Securities Fraud Investigation With The Schall Law Firm

‘We think the magnitude of the selloff is overdone,' analyst says.

DexCom's stock is headed for its worst selloff ever. Not everyone thinks it's justified.

Dexcom, which had its stock market debut in 2005, is headed for its worst day ever. The company reported disappointing revenue on Thursday and lowered its full-year guidance.

Dexcom shares plunge more than 40%, head for worst day on record

DexCom's (DXCM) second-quarter 2024 earnings surpass expectations while revenues fall short. The Sensor segment and CGM system expansion drive growth.

DexCom's (DXCM) Q2 Earnings Beat Estimates, Revenues Miss

NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of DexCom, Inc. ("DexCom") (NASDAQ:DXCM) concerning possible violations of federal securities laws. After the closure of market trading, on July 25, 2024, DexCom issued a press release announcing its financial results for the second quarter of 2024.

Levi & Korsinsky Announces an Investigation on Behalf of DexCom, Inc. (DXCM) Shareholders Who May Have Been Affected by Fraud

NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ:DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM INVESTIGATION NOTICE: BFA Law Announces an Investigation into DexCom, Inc. (NASDAQ:DXCM) for Securities Fraud; Investors who Lost Money are Urged to Contact the Firm

DexCom Inc DXCM reported second-quarter sales of more than $1 billion. That's up 15% year-over-year on a reported basis and 16% on an organic basis.

DexCom Faces Short-Term Challenges, But Market Growth Prospects Remain Strong: Analyst

Dexcom stock is crashing Friday after the glucose monitoring company reported dismal Q2 revenue and slashed its full-year sales guidance. Here's what you need to know.

Dexcom Stock Sinks on Sales Miss, Guidance Cut: What to Know

DexCom Inc (NASDAQ:DXCM, ETR:DC4), a medical device maker that produces continuous glucose monitoring systems for diabetes management, shares plunged by more than 40% after the company slashed its annual revenue forecast. The company now expects full-year revenue of $4 billion to $4.05 billion, representing organic growth between 11% and 13%, down from its earlier forecast of $4.2 billion to $4.35 billion.

DexCom slashes full-year sales forecast, shares plummet

DexCom reported mixed Q2 results with an earnings beat, but revenue missed expectations. The company lowered its full-year revenue guidance.

Why DexCom Stock Is Crashing Today

Dexcom (NASDAQ: DXCM ) stock is down over 40% after reporting disappointing revenue for the second quarter. It also lowered guidance for the rest of the year.

Dexcom (DXCM) Stock Is Plunging on an ‘Execution Miss.' What Is Really Going On?

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc.

DXCM INVESTIGATION ALERT: BFA Law Announces that it is Investigating DexCom, Inc. (NASDAQ:DXCM) for Securities Fraud; Investors who Suffered Losses are Encouraged to Contact the Firm

Shares of DexCom were spiraling after the medical device company surprised Wall Street with a steep cut to guidance.

DexCom Stock Plunges 37% After Earnings. GLP-1s Weren't the Problem.

DexCom (NASDAQ: DXCM ) stock is falling on Friday after the company released its earnings report for Q2 2024. DexCom starts its earnings report with adjusted earnings per share of 43 cents.

Why Is DexCom (DXCM) Stock Down 38% Today?

Olin

Zynex Inc

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday.

DexCom, Zynex, Olin And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Southwest Airlines

Brunswick

Huntington Bancshares

L3Harris

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Southwest Airlines Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Universal Display

Wingstop

Nasdaq-listed stocks have sustained a prolonged rally in recent months, reflecting investor optimism and robust market sentiment. However, in recent days, we have seen a notable pullback in several overvalued stocks, with investors increasingly favoring value over high flyers.

Get Your Money Out of These 3 Nasdaq Stocks by the End of July

Dexcom's shares sank about 38% in premarket trading on Friday after the medical device maker cut its annual revenue forecast, with analysts calling some of the issues 'self inflicted' rather than a broader market growth problem.

Dexcom plunges 40% after glucose monitor maker slashes sales forecast

DexCom reported disappointing earnings, missing estimates by 4% and lowering full-year growth expectations by ~$200 million. Sales in the U.S. market slowed, while international markets saw anemic growth, impacting the company's outlook. Markets blamed sales on poor sales execution, complicated by inefficient distribution channels. Despite strong earnings, DXCM faces challenges with distribution channels and growing competition, leading to a downgrade to Hold.

DexCom Q2: Surprising Earnings Miss With Hints Of Competitive Pressures

Shares in Dexcom (DXCM) lost more than a third of their value in extended trading Thursday after the medical devices company posted second-quarter results that came in below Wall Street expectations and slashed its annual revenue forecast.

Watch These Dexcom Price Levels as Stock Plunges After Guidance Slashed

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) investors concerning the Company's possible violations of federal securities laws. On July 25, 2024, after the market closed, DexCom announced its second quarter 2024 financial results, including $1.004 billion revenue, in a press release stating the Company's “execution did not meet [its] high standards.” The Company also lowered its fu.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of DexCom, Inc. (DXCM) on Behalf of Investors

DexCom, Inc. (NASDAQ:DXCM ) Q2 2024 Earnings Conference Call July 25, 2024 4:30 PM ET Corporate Participants Sean Christensen - Vice President of Finance, and Investor Relations Kevin Sayer - Chairman, President, and Chief Executive Officer Jereme Sylvain - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Jeff Johnson - Baird Magaret Andrew - William Blair Travis Steed - Bank of America Matt Taylor - Jefferies Danielle Antalffy - UBS Joanne Wuensch - Citibank Matthew O'Brien - Piper Sandler Sam Eiber - BTIG Mathew Blackman - Stifel Jason Bedford - Raymond James Steve Lichtman - Oppenheimer Mike Polark - Wolfe Research Shagun Singh - RBC Capital Markets Bill Plovanic - Canaccord Genuity Chris Pasquale - Nephron Matt Miksic - Barclays Operator Welcome to the Dexcom Second Quarter 2024 Earnings Release Conference Call. My name is Abby and I'll be your operator for today's call.

DexCom, Inc. (DXCM) Q2 2024 Earnings Call Transcript

DexCom (DXCM) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.34 per share a year ago.

News for DexCom Stock (DXCM)